We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

contact[at]op2lysis.com

pilelabs
  • The company
  • The Technology
  • Products
  • Indications
  • News
  • Contact
  • Français

Daily Archives: 15 September 2022

  1. Home
  2. 2022
  3. September
  4. 15
  • Op2Lysis
  • September 2022
  • Corporate
Orphan drug designation granted to OptPA for the treatment of non-traumatic spontaneous intracerebral hemorrhage by the European Commission
Read More

Articles récents

  • Retrospective – 2024 in a nutshell
  • Funding for the ThromboSTROKE collaborative research project
  • Sucessful DRF toxicology Study
  • Retrospective – 2023 in a nutshell
  • Nominated for the GALIEN USA 2023 award “Best Startup”

Archives

  • February 2025
  • October 2024
  • September 2024
  • January 2024
  • October 2023
  • September 2023
  • July 2023
  • January 2023
  • December 2022
  • September 2022
  • April 2022
  • January 2022

Catégories

  • Corporate
  • Event
  • Press Release
  • Technology
gym-footer-logo

Biotechnology company that researches and develops innovative medicines

Supported by
europe
bpi
wallonie

SItemap

  • Contact
  • home
  • Indications
  • Legal Notice
  • News
  • Products
  • The company
  • The Technology

Recent Posts

Nominated for the GALIEN USA 2023 award “Best Startup”
October 12, 2023
Retrospective – 2024 in a nutshell
February 01, 2025
Funding for the ThromboSTROKE collaborative research project
October 15, 2024

Contact

  • FRANCE: 117 avenue Victor Hugo, 92100 Boulogne-Billancourt, France BELGIUM: Légia Park, Boulevard Patience et Beaujonc, 3, 4000 Liège, Belgium

Op2Lysis © 2022 All Rights Reserved – Legal notice – web agency : Bridge Communication